Novel targets for therapy in TD β-Thalassaemia - European Medical Journal
×

Browse

Novel targets for therapy in TD β-Thalassaemia

|
Hematology

The second of our six-part series focusing on increasing awareness of β-thalassaemia features Khaled Musallam, Clinical Professor at the College of Medicine and Health Sciences at Khalifa University of Science and Technology in Abu Dhabi, UAE.

Musallam shares his expert insights into β-thalassaemia with our expert chair Jonathan Sackier. With a focus on conventional therapies and its pitfalls, topics discussed include novel therapies in transfusion dependent β -thalassaemia including gene 2 therapy/insertion, gene editing, luspatercept and mitapivat. This on-demand webinar also features a question and answer session, which sees the experts delving further into this important topic with questions from the live audience.

This is a scientific presentation and discussion for the purpose of scientific exchange. Neither the session nor the information presented or discussed are for the promotional purpose of influencing prescribing or treatment decisions.

This session may include information about investigational products and/or uses that are not approved for use in any country or in the country of your residence.

Prescribing decisions are made by healthcare professionals. Always refer to the approved product labelling before prescribing (e.g., SmPC, US Prescribing Information).